Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, Vey N, Haioun C, Colombat P, Rossi JF, Deconinck E, Lazreg F, Bergougnoux L, Delsol G, Attal M. Morschhauser F, et al. Among authors: milpied n. Ann Oncol. 2012 Oct;23(10):2687-2695. doi: 10.1093/annonc/mds202. Epub 2012 Jul 5. Ann Oncol. 2012. PMID: 22767588 Free article. Clinical Trial.
Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.
André M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn JY, Attal M, Fleury J, Milpied N, Nedellec G, Biron P, Tilly H, Jouet JP, Gisselbrecht C. André M, et al. Among authors: milpied n. J Clin Oncol. 1999 Jan;17(1):222-9. doi: 10.1200/JCO.1999.17.1.222. J Clin Oncol. 1999. PMID: 10458237
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haïoun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boué F, Taillan B, Lederlin P, Najman A, Thièblemont C, Montestruc F, Mathieu-Boué A, Benzohra A, Solal-Céligny P. Colombat P, et al. Among authors: milpied n. Blood. 2001 Jan 1;97(1):101-6. doi: 10.1182/blood.v97.1.101. Blood. 2001. PMID: 11133748 Free article. Clinical Trial.
Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France.
Foussard C, Desablens B, Sensebe L, François S, Milpied N, Deconinck E, Delwail V, Dugay J, Lamy T, Ghandour C, Le Mevel A, Maisonneuve H, Casassus P, Colombat P. Foussard C, et al. Among authors: milpied n. Ann Oncol. 1997;8 Suppl 1:49-52. Ann Oncol. 1997. PMID: 9187429 Clinical Trial.
Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy.
Limat S, Woronoff-Lemsi MC, Milpied N, Chartrin I, Ifrah N, Deconinck E, Gressin R, Colombat P, Cahn JY, Arveux P; Groupe Ouest Est d'étude des Leucémies et Autres Maladies du Sang (GOELAMS). Limat S, et al. Among authors: milpied n. Eur J Cancer. 2000 Dec;36(18):2360-7. doi: 10.1016/s0959-8049(00)00327-0. Eur J Cancer. 2000. PMID: 11094310 Clinical Trial.
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, Tilly H, Raemaekers J, van 't Veer MB, Milpied N, Cartron G, Pezzutto A, Spencer A, Reyes F, Dreyling M. Morschhauser F, et al. Among authors: milpied n. Ann Oncol. 2008 Feb;19(2):247-53. doi: 10.1093/annonc/mdm463. Epub 2007 Sep 28. Ann Oncol. 2008. PMID: 17906297 Free article. Clinical Trial.
451 results